Fusion Antibodies (LON:FAB) Stock Price Down 2% – Should You Sell?

Shares of Fusion Antibodies plc (LON:FAB) dropped 2% on Tuesday . The stock traded as low as GBX 9.80 ($0.12) and last traded at GBX 10 ($0.12). Approximately 3,455,756 shares changed hands during trading, a decline of 22% from the average daily volume of 4,450,999 shares. The stock had previously closed at GBX 10.20 ($0.13).

Fusion Antibodies Price Performance

The company has a 50 day moving average of GBX 5.71 and a two-hundred day moving average of GBX 4.29. The firm has a market cap of £8.77 million, a P/E ratio of -230.00 and a beta of 0.49. The company has a quick ratio of 2.36, a current ratio of 3.87 and a debt-to-equity ratio of 2.40.

Insider Activity

In related news, insider Adrian Kinkaid bought 83,728 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The shares were acquired at an average cost of GBX 4 ($0.05) per share, for a total transaction of £3,349.12 ($4,139.83). Insiders own 11.39% of the company’s stock.

Fusion Antibodies Company Profile

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.